Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.

About this Publication
Title
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promise.
Pubmed ID
15283897 (View this publication on the PubMed website)
Publication
Urol. Oncol. 2004; Volume 22 (Issue 4): Pages 358-61
Authors
Andriole GL, Reding D, Hayes RB, Prorok PC, Gohagan JK, PLCO Steering Committee
Affiliations
  • Division of Urologic Surgery, Washington University School of Medicine, Washington University in St. Louis, 4960 Children's Place, Campus Box 8242, St. Louis, MO 63110, USA. andrioleg@wustl.edu
Abstract

The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.

Related CDAS Studies